TY - JOUR AU - Dreyling, M. PY - 2017 DA - 2017// TI - Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up JO - Ann Oncol. VL - 28 UR - https://doi.org/10.1093/annonc/mdx223 DO - 10.1093/annonc/mdx223 ID - Dreyling2017 ER - TY - JOUR AU - Kohrt, H. E. PY - 2014 DA - 2014// TI - Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity JO - Blood VL - 123 UR - https://doi.org/10.1182/blood-2014-01-547869 DO - 10.1182/blood-2014-01-547869 ID - Kohrt2014 ER - TY - JOUR AU - Roit, F. PY - 2015 DA - 2015// TI - Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy JO - Haematologica VL - 100 UR - https://doi.org/10.3324/haematol.2014.107011 DO - 10.3324/haematol.2014.107011 ID - Roit2015 ER - TY - JOUR AU - Byrd, J. C. PY - 2013 DA - 2013// TI - Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia JO - N Engl J Med VL - 369 UR - https://doi.org/10.1056/NEJMoa1215637 DO - 10.1056/NEJMoa1215637 ID - Byrd2013 ER - TY - JOUR AU - Advani, R. H. PY - 2013 DA - 2013// TI - Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.42.7906 DO - 10.1200/JCO.2012.42.7906 ID - Advani2013 ER - TY - JOUR AU - Duong, M. N. PY - 2015 DA - 2015// TI - Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodies JO - MAbs VL - 7 UR - https://doi.org/10.4161/19420862.2015.989020 DO - 10.4161/19420862.2015.989020 ID - Duong2015 ER - TY - JOUR AU - Berglöf, A. PY - 2015 DA - 2015// TI - Targets for Ibrutinib Beyond B Cell Malignancies JO - Scand J Immunol VL - 82 UR - https://doi.org/10.1111/sji.12333 DO - 10.1111/sji.12333 ID - Berglöf2015 ER - TY - JOUR AU - Bojarczuk, K. PY - 2014 DA - 2014// TI - B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies JO - Leukemia VL - 28 UR - https://doi.org/10.1038/leu.2014.12 DO - 10.1038/leu.2014.12 ID - Bojarczuk2014 ER - TY - JOUR AU - Liston, D. R. AU - Davis, M. PY - 2017 DA - 2017// TI - Clinically relevant concentrations of anticancer drugs: a guide for nonclinical studies JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-16-3083 DO - 10.1158/1078-0432.CCR-16-3083 ID - Liston2017 ER - TY - JOUR AU - Hernandez-Ilizaliturri, F. J. PY - 2005 DA - 2005// TI - Immunomodulatory Drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model JO - Clin Cancer Res VL - 11 UR - https://doi.org/10.1158/1078-0432.CCR-05-0577 DO - 10.1158/1078-0432.CCR-05-0577 ID - Hernandez-Ilizaliturri2005 ER - TY - JOUR AU - Zhang, L. PY - 2009 DA - 2009// TI - Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo JO - Am J Hematol VL - 84 UR - https://doi.org/10.1002/ajh.21468 DO - 10.1002/ajh.21468 ID - Zhang2009 ER - TY - JOUR AU - Wu, L. PY - 2008 DA - 2008// TI - lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells JO - Clin Cancer Res VL - 14 UR - https://doi.org/10.1158/1078-0432.CCR-07-4405 DO - 10.1158/1078-0432.CCR-07-4405 ID - Wu2008 ER - TY - JOUR AU - Wang, M. PY - 2012 DA - 2012// TI - Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial JO - Lancet Oncol VL - 13 UR - https://doi.org/10.1016/S1470-2045(12)70200-0 DO - 10.1016/S1470-2045(12)70200-0 ID - Wang2012 ER - TY - JOUR AU - Ruan, J. PY - 2017 DA - 2017// TI - Initial treatment with lenalidomide plus rituximab for mantle cell lymphoma: 5-year follow-up and correlative analysis from a multi-center phase II study JO - Blood VL - 130 ID - Ruan2017 ER - TY - JOUR AU - Chong, E. A. PY - 2015 DA - 2015// TI - Combination of lenalidomide and rituximab overcomes rituximab resistance in patients with indolent B-cell and mantle cell lymphomas JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-14-2221 DO - 10.1158/1078-0432.CCR-14-2221 ID - Chong2015 ER - TY - JOUR AU - Jerkeman, M. PY - 2018 DA - 2018// TI - Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial JO - Lancet Haematol. VL - 5 UR - https://doi.org/10.1016/S2352-3026(18)30018-8 DO - 10.1016/S2352-3026(18)30018-8 ID - Jerkeman2018 ER - TY - JOUR AU - Mossner, E. PY - 2010 DA - 2010// TI - Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity JO - Blood VL - 115 UR - https://doi.org/10.1182/blood-2009-06-225979 DO - 10.1182/blood-2009-06-225979 ID - Mossner2010 ER - TY - JOUR AU - Parrott, M. PY - 2018 DA - 2018// TI - A systematic review of treatments of relapsed/refractory mantle cell lymphoma JO - Clin Lymphoma Myeloma Leuk VL - 18 UR - https://doi.org/10.1016/j.clml.2017.10.004 DO - 10.1016/j.clml.2017.10.004 ID - Parrott2018 ER -